Key statistics
As of last trade, Akari Therapeutics PLC (CLA:FRA) traded at 1.17, 23.81% above the 52 week low of 0.945 set on Apr 19, 2024.
52-week range
Open | 1.32 |
---|---|
High | 1.32 |
Low | 1.17 |
Bid | 1.17 |
Offer | 1.29 |
Previous close | 1.41 |
Average volume | 53.56 |
---|---|
Shares outstanding | 1.24m |
Free float | 1.12m |
P/E (TTM) | -- |
Market cap | 36.40m USD |
EPS (TTM) | -2.98 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 14:51 GMT.
More ▼
Announcements
- Akari Therapeutics Regains Full Nasdaq Compliance
- Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
- Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
- Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
- Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
- Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
- Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
More ▼